ENANTA PHARMACEUTICALS INC
NASDAQ: ENTA (Enanta Pharmaceuticals, Inc.)
最近更新时间: 9小时之前11.00
0.92 (9.13%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Enanta Pharmaceuticals, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.9 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -2.5 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.39 |
|
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.57% |
| 机构持股比例 | 87.24% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Krensavage Asset Management, Llc | 30 Jun 2026 | 2,866,138 |
该时间范围内无数据。
投资组合